Results: Here, we show that combination therapy with two fully human mAbs against an immunodominant MV antigen, H3 (H3L), and an EV antigen, B5 (B5R), provides significantly better protection against disease and death than either single human monoclonal or human vaccinia immune globulin, the currently licensed therapeutic for side effects of smallpox vaccination. Conclusions: The preclinical studies validate that this combination of mAbs against H3 and B5 is a promising approach as a poxvirus infection treatment for use in humans.
Smallpox is a highly lethal viral infection affecting humans (30% mortality) [1, 2] , which can spread rapidly through a population. Smallpox is a top bioterrorism concern and is frequently considered the greatest bioterrorism danger [1, [3] [4] [5] [6] [7] . The smallpox vaccine consists of live vaccinia virus (VACV) and, from a public health perspective, is the gold standard of vaccines because it has led to the complete eradication of wild smallpox (variola virus) from the human population [2] . Renewed fears that smallpox might be deliberately released in an act of bioterrorism have led to a resurgence in the study of treatment of smallpox infection. Individuals <35 years old (approximately 50% of the population) have not been vaccinated against smallpox, leaving them highly susceptible in the event of an outbreak. There is also substantial interest in better therapeutics for the treatment of the rare but severe side effects of the smallpox vaccine. There is an active smallpox vaccination campaign in the US military, and vaccinia immune globulin (VIG) is used to treat the rare side effects of vaccination. Finally, there is also interest in therapeutics for treatment of other poxviruses, such as monkeypox, which is transmitted among rodent populations. A monkeypox outbreak occurred for the first time in the USA in 2003 [8] [9] [10] [11] .
The smallpox vaccine is administered as a series of 3-15 skin pricks using a bifurcated needle [12] . Four major smallpox vaccine strains were used during the massive vaccination programme (Dryvax ® ). In the USA, the New York City Board of Health VACV (VACV NYCBOH ) strain has been used as the vaccine [12] . The vaccine was commercially produced as Dryvax ® (also known as the VACV Wyeth strain or substrain). A clonal isolate of VACV NYCBOH , ACAM2000 ® , has now been developed as a cell-culture-derived smallpox vaccine, with a comparable ® is now the currently licensed smallpox vaccine in the USA [13] . The vaccine 'take' is observed as the formation of a pustule starting on approximately day 5 post-vaccination and lasting for 1-2 weeks thereafter [12, 14, 15] . The vaccine provides outstanding immunity, but could cause a variety of side effects that have been reason for concern [16] [17] [18] . Common side effects include fever and satellite pox (additional pustules near the primary pustule, also called mild generalized vaccinia). More severe side effects include progressive vaccinia, generalized vaccinia, encephalitis, vaccinia keratitis and eczema vaccinatum [14, 16, 17, 19] .
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Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model
Currently, VIG is the only licensed therapeutic to treat the side effects of smallpox vaccination [16, 18] . In addition, VIG has shown efficacy against smallpox itself in clinical trials in the early 1960s. A meta-analysis of the four available controlled studies carried out with VIG indicates that VIG is protective and reduces smallpox cases by approximately 75% [20] . VIG reduced the spread of smallpox outbreaks when administered at the same time as smallpox vaccination to smallpox contacts [20] [21] [22] [23] . An impressive study demonstrating the use of passive immunotherapy was published in 1941 [24] . In this study, a smallpox outbreak initially claimed the lives of 3 out of 10 patients. When patient care was expanded to include administration of high-titre smallpox-specific convalescent serum at the first signs of disease, the mortality rate dropped to 0% (0 deaths out of 250 subsequent smallpox infections reported) and the treated patients experienced fewer smallpox scars after recovery [24] .
There is also compelling animal model data supporting the efficacy of VIG against pathogenic poxvirus infections. Licensed VIG has demonstrated efficacy by in vitro neutralization of VACV and in vivo treatment of severe combined immunodeficiency (SCID) mice infected with VACV [18, [25] [26] [27] [28] [29] . In rhesus macaque monkeypox studies, it was demonstrated that smallpox vaccine-elicited neutralizing antibodies were necessary for protection. Furthermore, it was shown that neutralizing antibodies were sufficient for protection against a lethal monkeypox challenge, as administration of VIG to unvaccinated macaques prior to monkeypox challenge provided protection [30] . Although animals developed skin lesions (that is, pox) in a dosedependent manner with an inverse relationship to the amount of VIG administered, they were all fully protected from lethal infection [30] .
Unfortunately, VIG is a poorly characterized, variable human product that is of limited potency [18, 20] . Each of these issues is a major problem for biodefence preparedness against a smallpox bioterrorism event. These problems with VIG have led to great interest in the development of an alternative high-potency antismallpox immunotherapy free of these issues.
Our goal is to develop a highly efficacious and standardized monoclonal antibody (mAb) antismallpox therapeutic that can be produced in large quantities and stored long-term. Poxviruses (VACV, variola/smallpox and monkeypox) have two virion forms, intracellular mature virions (MV, IMV) and extracellular enveloped virions (EV, EEV), each with distinct structure and biology. Importantly, the two virion forms do not share any surface proteins; therefore, the virion forms are immunologically distinct and are not neutralized by antibody of a single specificity [31] . VIG contains both anti-MV and anti-EV antibodies [29, [32] [33] [34] [35] [36] [37] ; therefore, an effective VIG replacement therapeutic product should contain one anti-MV mAb and one anti-EV mAb, each capable of neutralizing their respective virion form.
In the current study, we reported characterization of mAbs against H3 and B5 (MV and EV antigens, respectively), demonstrating their efficacy against VACV in an in vivo model of progressive vaccinia, using VIG as the benchmark for efficacy.
Methods
Viruses
VACV NYCBOH vaccine strain was grown to a second or third passage stock from an aliquot of Dryvax ® . Stocks of VACV NYCBOH and the VACV Western Reserve strain (VACV WR ) were grown as described previously [36, 38, 39] . A laboratory stock of the ACAM2000 ® clone of VACV NYCBOH was also used in later experiments. The ACAM2000 ® stock was generated by singlepassage amplification in HeLa cells of ACAM2000 ® VACV (Acambis Inc., Cambridge, MA, USA).
Mice and infections
Female SCID mice on the BALB/c background (CBy. Smn.CB17 PRKdc SCID/J ) between 7 and 12 weeks of age were purchased from Jackson Laboratories (Sacramento, CA, USA) and used in experiments at approximately 8 weeks old. Animals were acclimatized for at least 1 week prior to infection. Animal health was assessed prior to infection. Five animals per cage were housed in microisolator cages in ventilated racks. All animal experiments were conducted using the Institutional Animal Care and Use Committee approved animal protocols.
Animals received food and acidified water (pH 2.5-3.5) ad libitum. 
Body weight
After infecting animals on day 0, weights were taken for the initial body weight measurement. Body weights were then taken every other day, beginning 3 days post-infection. Body weights were recorded until the animal reached 70% of initial body weight in all experiments (except the experiment investigating the in vivo protection of anti-H3 plus anti-B5 versus VIG, wherein 75% of initial body weight was the end point) or if other external health variables became present for which euthanasia was the only humane course of action. Studies were ended on day 90.
Clinical score
Mice developed lesions (pox) on the tail at 6-8 days post-infection. The method of clinical scoring evaluates the number and severity of the lesions [19] . The tail was scored in three parts: the base, middle and tip of the tail. The lesions were evaluated as follows: score 0, no pox; score 1, 1-3 pox; score 2, ≥3 pox and score 3, ≥3 pox and erupted. An additional evaluation of the paws was taken. A score of 1 was given if the animal only had pox on its hind paws and a score of 2 was given when the animal had pox on the front and hind paws. The maximum score was 11 (for example, base =3, mid =3, tip =3 and paws =2). Clinical scores usually stabilized at 15-20 days post-infection.
Generation of recombinant H3
For cloning of a full-length H3 (H3L), the DNA from cells infected with the VACV NYCBOH strain was used as a PCR template. The sequence encoding the fulllength open reading frame of VACV H3L was amplified by reverse transcription PCR using primers H3L forward NdeI pET-15b (5′-AGAGAGAGACATATGG CGGCGGCGAAAACT-3′) and H3L reverse Bam HI pET-15b (5′-AGAGAGAGACATATGGCGGCGGC GAAAACT-3′). As a cloning intermediate, this PCR product was cloned into the TA-topo2.1 vector following manufacturer's instructions (Invitrogen Corp., Carlsbad, CA, USA). This H3L-TA-topo2.1 plasmid was then used as a template for PCR using primers H3L forward NheI pET28 (5′-AGAGAGAGAGCTAG CGCGGCGGCGAAAACT-3′) and H3L reverse XhoI pET28 (5′-CTCTCTCTCTCTCGAGTTAGATAAAT GCGGTAACGA-3′). The amplified full-length PCR product was digested with NheI and XhoI and ligated into the NheI and XhoI sites of the bacterial expression vector pET28a to create pET28a-full-length-H3L-His that encodes an H3L with a C-terminal 6xHis tag (HisTag ® ; Invitrogen Corp.).
H3L production and protein purification
To produce H3L-His in bacteria, the expression vector pET28a-full-length-H3L-His was transformed into BL21 (DE3) pLysS competent cells and bacterial cultures were induced to express H3L-His by a 2 h incubation of diluted (1:20) overnight cultures in 1 mM isopropyl-β-d-thiogalactopyranoside. Cells were harvested by centrifugation for protein purification. Recombinant full-length H3L with N-terminal HisTag ® was purified by metal chelate affinity chromatography with Ni Sepharose 6 Fast Flow resin (GE Healthcare, Pittsburgh, PA, USA). Bacterial cells were lysed with microfluidizer (model M10L; Microfluidics, Inc., Newton, MA, USA). Lysis buffer included 0.5% Triton X-100 (EMD Chemicals Inc., Gibbstown, NJ, USA) and the chromatography was performed in the presence of an appropriate non-ionic detergent, for example, 0.5% Triton X-100 or 0.58% octyl glucoside (Calbiochem, EMD Chemicals Inc.). H3L was eluted from the column with 200 mM imidazole and subsequently dialyzed against 20 mM Na phosphate buffer (pH 8.0), 0.25M NaCl, 10% glycerol and appropriate detergent. Protein concentration was determined by DC Lowry protein assays (BioRad, Hercules, CA, USA) using bovine serum albumin (Pierce Biotechnology, Rockford, IL, USA) as a standard in the same buffer.
Antibodies
Mouse antibody clone 41 was derived from a BALB/ cJ mouse infected twice with VACV WR . For the generation of human antibodies, Kirin Medarex (KM) mice were immunized subcutaneously with 25-50 µg of recombinant H3 or B5 proteins emulsified in complete Freund's adjuvant (mixed 1:1). KM mice were generated by cross-breeding double transchromosomic mice and transgenic mice [40] . KM mice possess human chromosome fragments containing the entire human immunoglobulin (Ig) heavy chain locus and the yeast artificial chromosome (YAC) transgene for 50% of the human Ig kappa light chain locus. The KM mice were engineered to express neither endogenous Ig (µMT-/-) nor kappa light chain (κ-/-) and were used to obtain human mAbs. Generation of recombinant B5, immunizations of mice and generation of hybridomas were as described previously [39, 41] . Human antidinitrophenol (DNP) IgG1 mAb was derived from a chinese hamster ovary (CHO) transfectant clone kindly provided by Hideaki Yoshida from Kyowa Hakko Kirin Co., Ltd, Tokyo, Japan. For antibody purification, hybridomas or CHO stable transfectants were cultured in roller bottles or Wave™ bioreactors with hybridoma serum-free medium (Invitrogen Corp.) supplemented with ultra-low IgG fetal bovine serum (Invitrogen Corp.) or CHO-CD XP TM serumfree medium (Irvine Scientific, Santa Ana, CA, USA), respectively. mAbs were purified from conditioned culture media using recombinant Protein A-Sepharose Fast Flow gel (GE Healthcare) as described previously [41] . The purified antibodies were quantitated by the Lowry protein assay using bovine IgG (Pierce Biotechnology) as a standard and they were stored in aliquots at -80°C and diluted in phosphate-buffered saline (PBS) immediately prior to injection, as needed.
VIG (53 mg/ml) was a kind gift from Dorothy Scott and Robert Fisher (US Food and Drug Administration, Bethesda, MD, USA). VIG was stored at 4°C and diluted into PBS immediately prior to injection, as needed. Human recommended dose was 50 mg/kg [25] . Maximum adult BALB/c SCID female mouse mass was 25 g; therefore, the human equivalent VIG dose for a mouse based on mass was calculated to be 1.25 mg.
Virus neutralization assays
VeroE6 cells were seeded at 1.5×10 5 cells/well into 24-well Costar plates (Corning, Inc., Corning, NY, USA) and used the following day (at 75-90% confluence). Three different VACV MV neutralization assays were used: overnight neutralization, 1 h with no complement and 1 h plus complement. Overnight VACV MV neutralization was carried out as reported previously by Newman et al. [42] . Briefly, diluted mAb samples (final concentration of 10 µg/ml) in D10 (Dulbecco's modified Eagle's medium plus 10% fetal calf serum plus penicillin-streptomycin-glutamine) were incubated overnight at 37°C in 5% CO 2 in an equal volume (50 µl) of sonicated VACV WR MV (1×10 4 PFU/ ml), as described previously [43] . Fetal calf serum was heat-inactivated prior to use to eliminate complement function. In quantitative dose titration experiments twofold dilution of mAb samples was used. VACV MV alone was used in each assay as a negative control. For direct VACV MV neutralization, diluted mAb samples (final concentration of 10 µg/ml) were incubated for 1 h at 37°C in 5% CO 2 in an equal volume (50 µl) of sonicated VACV WR MV. VACV MV alone was used as a negative control. For VACV MV neutralization in the presence of complement, diluted mAb samples were incubated for 1 h with the virus (as described above) in the presence of 1% (final concentration) sterile baby rabbit complement (Cedarlane Laboratories, Burlington, ON, Canada). VACV MV samples plus 1% baby rabbit complement were used as negative controls. Plaque assays were then carried out as described previously [36, 38] .
Statistical analyses
Tests were performed using Prism 5.0 (GraphPad, San Diego, CA, USA). The significance of the survival curves was calculated using Mantel-Cox statistical analysis of Kaplan-Meier curves. Statistical significance of cumulative weight loss was calculated as the net area under the curve (AUC; body weight versus time) for each mouse and then the statistical significance was determined between experimental groups by two-tailed unpaired Student's t-tests with 95% confidence intervals without assuming a normal distribution (Welch's correction). Statistical analyses of time to 5% weight loss was carried out by tabulating the days until weight first dropped to <95% of starting weight for each mouse, and the statistical significance was calculated using two-tailed unpaired Student's t-tests with 95% confidence intervals without assuming a normal distribution (Welch's correction). Clinical score statistical analyses from a single time point were carried out using the Mann-Whitney U test. Cumulative clinical score data was calculated as the AUC (clinical score versus time) for each mouse and the statistical significance was determined between experimental groups by two-tailed unpaired Student's t-tests with 95% confidence intervals without assuming a normal distribution (Welch's correction). Unless otherwise indicated above, statistics were carried out using two-tailed unpaired Student's t-tests with 95% confidence intervals.
Results
Characterization of murine anti-H3 mAb
Anti-H3 murine mAbs were generated using conventional techniques and then screened for neutralization of VACV in vitro. The neutralization potency of each mAb was determined by quantitative dose titrations, measuring the lowest mAb concentration able to inhibit VACV infection by 50%, as measured by plaque assays (PRNT 50 ). Clone 41 exhibited the most effective neutralization. Neutralization was observed in a standard overnight neutralization assay ( Figure  1A ). Partial neutralization was observed in a 1 h neutralization assay ( Figure 1B ). This result is somewhat different from a previous report [44] , in which good neutralization was observed after short incubation of virus with antibody, perhaps because of residual complement present in previous experiments or differences in the cell lines used for virus production. Enhanced neutralization was observed by mAb clone 41 in the presence of 1% complement in a 1 h neutralization assay ( Figure 1C) .
In vivo protective efficacy of murine anti-H3 against progressive vaccinia
To examine in vivo efficacy of the anti-H3 mAb clone 41, we used SCID mice infected with VACV as a small animal model of human progressive vaccinia. In this system, SCID mice were infected with smallpox vaccine VACV NYCBOH and then tracked for weight loss, pox formation and survival. This model has been used by VIG vendors [28] and the US Food and Drug Administration [29] to measure the efficacy of VIG. This model is valuable because it uses the human vaccine strain of vaccinia and because it models immunodeficient or immunocompromised humans, a primary group of patients of concern for failure to control VACV and for development of progressive vaccinia or other life threatening side effects (clinical indications for which VIG is licensed). Treatment with a human mg/kg equivalent dose of VIG was able to extend life by >1 week in this model [28, 29, 33] . Because SCID mice are fully immunodeficient, a complete cure is not expected from a single dose of therapeutic antibody. Nevertheless, this animal model readout of life extension correlates with the ability of VIG to ameliorate severe VACV side effects in humans [18] and provides substantial (approximately 75%) post-exposure prophylaxis against smallpox [20] . Because this assay uses the human smallpox vaccine strain, models vaccinia infection in an immunocompromised setting and has been previously used with VIG, this animal model served as the primary benchmark by which we measured successful candidate mAbs. The mAbs were directly tested against VIG as the 'standard of care'. mAbs were considered non-inferior to VIG if they extended survival time by an equivalent number of days and mAbs were considered superior to VIG if they extended survival time longer than VIG.
VACV NYCBOH was titrated in SCID mice and the disease progression observed was consistent with previous publications (Figure 2A) . Groups of SCID mice were then infected intravenously with 5×10 4 PFU VACV NYCBOH after treatment with a single dose of anti-H3 mAb clone 41, VIG or PBS 1 day prior to infection (day -1). Protection against weight loss was observed for treatment with anti-H3 clone 41 or VIG ( Figure 2B ). Clinical scores were also measured, quantifying the number and severity of pox lesions on the tail and footpads ( Figure  2C ). Anti-H3 clone 41 and VIG both provided partial protection against the development of pox lesions mAb clone 41 versus PBS; P<0.008) of SCID mice infected with VACV WR ( Figure 2D ). VIG also exhibited efficacy at delaying weight loss (VIG versus PBS; P<0.02) and extending survival time (VIG versus PBS; P<0.005), but not as robustly as anti-H3 treatment ( Figure 2D ).
Characterization of human anti-H3 mAb
Descriptions of the development of murine anti-B5 mAbs have been reported [38] , including efficacy of the mAb number B126 in vivo using the mouse intranasal VACV WR infection model, which is a small animal model for respiratory smallpox; the SCID mouse model was also used [38] . Having shown proof of principle with murine mAbs (Figures 1 and  2 and [38] ), we then moved to develop fully human antibodies against H3 and B5 as our candidate therapeutics for use in humans. Kyowa Hakko Kirin California, Inc. (La Jolla, CA, USA) used proprietary transchromosomic mice, which possess the human Ig loci and thereby produce fully human antibodies [40] , to develop fully human mAbs against H3 and B5. The characterization of the fully human B5 mAbs has been described elsewhere [39] . Human anti-H3 mAbs were characterized in vitro and top candidate hV26 exhibited good neutralization of VACV ( Figure  3A and 3B), whereas clone hV25 exhibited no neutralization ( Figure 3B ). When compared side-by-side, murine anti-H3 clone 41 and human anti-H3 hV26 exhibited comparable in vitro virus neutralization activity to each other (SC, data not shown).
In vivo protective efficacy of human anti-H3 against progressive vaccinia
The fully human anti-H3 mAb hV26 was tested for efficacy in the in vivo progressive vaccinia model. Significant protection against weight loss was observed for treatment with human anti-H3 hV26 (human anti-H3 hV26 versus PBS; P<0.003; Figure 3C ). A significant increase in survival was also observed (human anti-H3 hV26 versus PBS; P<0.004; Figure  3D ). Anti-H3 mAb hV26 provided equivalent protection to that of VIG, both for weight loss (anti-H3 mAb hV26 versus VIG; P= not significant) and survival (anti-H3 mAb hV26 versus VIG; P= not significant). Clinical scores were measured, quantifying the number and severity of pox lesions on the tail and footpads ( Figure 3E ). Both human anti-H3 hV26 and VIG provided significant protection against the development of pox lesions, both in terms of magni Figure 4B ). Pox lesion reduction was similar between hV26 and VIG.
In vivo protective efficacy of human anti-B5 against progressive vaccinia
The fully human anti-B5 mAb h101 was tested for efficacy in the in vivo progressive vaccinia model. The fully human mAb h101 performed comparably to the murine anti-B5 mAb in vivo, showing efficacy comparable to or better than VIG treatment ( Figure  5A and 5B). Cumulative weight loss was significantly ameliorated by single treatment with h101 (h101 versus PBS; P<0.007 by AUC analysis). As a measure of early disease, the number of days until 5% weight loss was quantitated. Time to 5% weight loss was significantly better in h101-treated mice (h101 versus PBS; P<0.002; Figure 5B ) and was comparable to or better than VIG. Pox lesions were also significantly inhibited after treatment with human anti-B5 h101 (human anti-B5 versus PBS; P<0.0001; Figure 5C ), which was comparable to VIG treatment. Not only did h101 treatment delay onset of disease ( Figure 5B and 5C), it also extended overall lifespan, as animal survival was significantly improved after treatment with h101 (h101 versus PBS; P<0.0001; Figure 5D ). Dose titrations of human anti-B5 h101 were performed to determine potency ( Figure 6 ). A control comprising irrelevant human IgG1 mAb (DNP hapten-specific) was also included as a more specific negative control. Results with PBS or anti-DNP IgG1-treated mice were comparable ( Figure 6 ). Compared with control human IgG1 mAb (DNP), weight loss was substantially improved in mice receiving 100, 50 (P<0.02) or 25 µg anti-B5 mAb h101 (P<0.02; Figure  6A) ; however, the 100 µg h101 group did not reach significance because of an early death of one mouse. Delay of early stage disease, measured as time to 5% weight loss, was significantly better in h101-treated mice than in control mAb-treated mice (the P-values for h101 100, 50 and 25 µg were P<0.03, P<0.006 and P<0.005, respectively; Figure 6B ). All doses of h101 treatment were equal to or better than VIG, as measured by time to 5% weight loss ( Figure 6B ) or overall weight loss kinetics ( Figure 6A ). Pox lesions were also significantly inhibited at all doses of h101 treatment compared with control IgG1 (DNP; the P-values for 100, 50 and 25 µg were P<0.02, P<0.02 and P<0.03, respectively; Figure 6C ). Survival was extended in all h101-treated mouse groups, but did not reach statistical significance because of the small group sizes (n=5; Figure 6D ). Larger group sizes were used in subsequent studies.
In vivo protective efficacy of combination human anti-H3/anti-B5 against progressive vaccinia
Our proposed therapeutic was a combination of an anti-MV and anti-EV antibody; therefore, we tested whether combination therapy with anti-H3 (hV26) plus anti-B5 (h101) fully human mAbs exhibited increased protective efficacy. Groups of SCID mice were infected with VACV NYCBOH after treatment with a single dose of human anti-H3 mAb hV26, human anti-B5 mAb h101, human anti-H3/B5 together, VIG or control human IgG1 at day -1. As before, significant protection against weight loss and pox formation was observed after treatment with anti-H3 or anti-B5 mAb alone, compared with treatment with an irrelevant mAb (for weight loss, the P-values for anti-H3 versus irrelevant mAb and anti-B5 versus irrelevant mAb were P<0.005 and P<0.004, respectively; for pox formation, the P-values for anti-H3 versus irrelevant mAb and anti-B5 versus irrelevant mAb were P<0.0001 and P<0.0001, respectively; Figure 7) . A 50 µg combination treatment was significantly better than control IgG1 as measured by the early disease parameter of days to 5% weight loss (P=0.0009), the end-stage disease parameter of survival (P<0.0001), total weight loss disease burden (P=0.0006) or pox lesion development (day 17; P<0.0001). A lower dose of combination treatment of anti-H3/B5 was also tested (25 µg each), with results that were similar to single treatment with either mAb alone ( Figure 7 ) and that were still statistically significantly better than control IgG1 by time to 5% weight Impressively, 50 µg (each) anti-H3/B5 combination therapy provided significantly enhanced efficacy compared with VIG ( Figure 7A ). This was quantifiable, as measured by delay of early disease (time to 5% weight loss; P=0.07; Figure 7B ), total weight loss disease burden (AUC; P<0.04; Figure 7A ), severity of pox lesions (clinical score; P=0.06; Figure 7C ) or survival (P<0.02; Figure 7D ). Combination therapy with 50 µg anti-H3/B5 also provided substantially enhanced efficacy compared with single therapy with either mAb alone ( Figure 7A , 7B, 7C and 7D), although these differences did not reach statistical significance, except survival of 50 µg anti-H3/B5 combination versus 50 µg hV26 alone (P<0.04). The borderline significance of combination therapy in comparison with single therapy with either mAb alone was a result of underpowered experiment group sizes, as combined statistical analyses of the two largest experiments showed that combination mAb therapy robustly outperformed VIG (meta-analysis; Table 1 ) and provided a statistically significant improvement over single mAb therapy in survival (P=0.006), overall weight loss (P=0.049) and time to 5% weight loss (P=0.046; Table 1 
Discussion
Antibodies against VACV and smallpox are crucial components of the protective immunity elicited by the smallpox vaccine [31, 45] . mAbs against VACV MV and EV have been previously demonstrated to be protective in a variety of small animal experimental models [35, 37, 38, [46] [47] [48] [49] [50] . Our primary goals here were to develop human anti-MV and anti-EV mAbs that could be used in combination as a clinical therapeutic that would be a replacement for VIG. The rationale for this approach is that human mAbs can be manufactured (under well-defined conditions) in virtually unlimited quantities. Furthermore, mAbs are expected to have a higher specific activity than polyclonal VIG, resulting in the twin benefits of lower doses and higher efficacy.
We demonstrate here that fully human mAbs against either H3 or B5 were efficacious at providing protection equal to VIG. Furthermore, a combination of the two mAbs provided impressively increased protective efficacy beyond that observed for VIG; therefore, the preclinical studies validate that this combination of human antibodies is a promising approach as a poxvirus therapeutic for use in humans. In future studies, post-exposure prophylaxis against VACV will be tested. Combination therapy with human antibodies might also be a useful treatment for smallpox infections. 
